top of page

Brainomix, an Oxford, UK based company that uses AI to help front line physicians analyze CT scans for stroke damage and interstitial lung disease, announced an $18M series C raise today

  • blonca9
  • Mar 20
  • 1 min read

Co-Founder and CEO Michalis Papadakis describes the unmet need for a quick, accurate assessment of stroke damage by front line physicians, who otherwise might not be experts in the area. Plus, moving the technology to lung disease and beyond.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page